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Our aim was to compare serum levels of selected biological parameters in diﬀerent phases of multiple myeloma (MM) and
monoclonal gammopathy of undetermined signiﬁcance (MGUS) to determine their diagnostic and prognostic potential. A cohort
of 234 individuals was assessed for serum levels of hepatocyte growth factor (HGF), syndecan-1/CD138 (SYN), and osteopontin
(OPN). The patients with MM (N = 156) were divided into 3 groups: at the time of diagnosis (N = 45), in relapse/progression
(N = 56), and in remission (N = 50). The analysis revealed signiﬁcant diﬀerences of all three parameters in comparison of
active and remission phase MM. Moreover, the parameters in active myeloma were signiﬁcantly higher than in MGUS. Within the
comparison of active disease (newly diagnosed and relapsing), there was no signiﬁcant diﬀerence. Similar results were in remission
phase MM and MGUS. There was no relationship of pretreatment levels of the parameters to therapeutic response. We conclude
that serum levels of HGF, OPN, and SYN correspond to the activity of MM and might become useful in diﬀerentiation of MGUS,
asymptomatic MM, and overt/symptomatic form of MM. The levels of all three parameters behave accordingly with MM activity.
Pretreatment measurement without the assessment of their kinetics, however, has no relationship to therapeutic response.
1.Introduction
Multiple myeloma (MM) is a very heterogeneous disease
with a diﬀerent manifestation, course, and response to ther-
a p y .T h eb i o l o g yo fm a l i g n a n tc e l la sw e l la st h em i c r o e n v i -
ronment of the bone marrow accountforsuchheterogeneity,
oﬀering novel targets for therapeutic approach. Several
angiogenic cytokines, bone metabolism markers, cytoadhe-
sive molecules, and other parameters with close relationship
to the pathogenesis of MM were conﬁrmed to have signif-
icant diﬀerences in monoclonal gammopathy of undeter-
mined signiﬁcance (MGUS) and in diﬀerent phases of MM
[1]. Some of them were identiﬁed as growth factors, cell
cycle modiﬁcators, or even potent prognosticators where-
as the role of many others is still not fully understood.
Based on recent ﬁndings that the serum levels of selected
biological parameters might have a direct relationship to
therapeutic outcome in patients with MM, we analyzed our
historical cohort of patients in order to ﬁnd convenient tools
for diagnostic approach as well as for the risk stratiﬁcation of
patients with MGUS and MM.
Out of more than 20 biological parameters, we selected
three with the highest rank of signiﬁcant relationship to
MM pathogenesis in previous studies [1–5]. These are the
hepatocyte growth factor (HGF), syndecan-1 (SYN), and
osteopontin (OPN).
The aim of our study was to estimate their diagnostic
value in diﬀerent phases of multiple myeloma and in MGUS,
and to deﬁne whether their pretreatment levels can be used
to predict therapeutic response.2 The Scientiﬁc World Journal
2. Patientsand Methods
Weretrospectivelyanalyzedacohortof234individuals—156
patients with multiple myeloma and 78 patients with mono-
clonal gammopathy of undetermined signiﬁcance (MGUS),
who were assessed for serum levels of HGF, SYN, and
OPN. The patients with MM were divided into three
separate groups: at the time of diagnosis (N = 41), in
relapse/progression (N = 65), and in remission (N = 50).
Patients with active disease (i.e., at the time of diagnosis
and in relapse/progression, N = 106) were then assessed for
therapeutic response. Nonresponders (N = 54) were deﬁned
by achievement of less than 50% decrease of monoclonal
immunoglobulin, andpatientswhoresponded(N = 52)had
more than 50% reduction of monoclonal immunoglobulin.
A subanalysis of 27 patients responding after autologous
peripheral blood stem cell transplantation (ASCT) was
carried out, deﬁning also the diﬀerences between the serum
levels of HGF, SYN, and OPN in patients achieving complete
remission (CR) and very good partial remission (VGPR)
according to IMWG criteria in comparison with patients
who achieved partial remission (PR) only. In the rest of the
patients who were treated by conventional chemotherapy
without ASCT, the numbers of patients achieving PR and
>PR were uneven, precluding a valid statistical analysis.
The MM patients were treated using high-dosed
chemotherapy with support of autologous stem cell trans-
plantation (31%, induction treatment using VAD regimen,
V: vincristine, A: adriamycin, D: dexamethasone, condi-
tioning with Mel200), thalidomide-based regimens (39%,
regimens MPT and CTD, M: melphalan, P: prednisone,
T: thalidomide, C: cyclophosphamide, D: dexamethasone),
and a historical group using conventional chemotherapy
(30%, regimens MP, VBMCP, and VAD, V: vincristine, B:
BCNU, M: melphalan, C: cyclophosphamide, P: prednisone,
A: adriamycin, D: dexamethasone).
Serum levels of hepatocyte growth factor (HGF), osteo-
pontin (OPN), and syndecan-1/CD138 (SYN) were mea-
sured using the technique of quantitative sandwich enzyme
immunoassay at the Department of Clinical Biochemistry.
Levels of each parameter were then assessed within individ-
ual groups of MM and MGUS patients. In all patients, the
assessment was carried out at the time of diagnosis, and in
patients undergoing ASCT at the time of diagnosis and also
on the day +100 after autologous transplantation. Finally,
we compared the relationship of pretreatment serum levels
of each parameter (HGF, OPN, and SYN) with therapeutic
response.
The characteristics of the whole cohort are summarized
in Table 1. Evaluation of cytogenetics was not performed in
all the patients, and, therefore, the results were not included
in the analysis.
Thedatawereassessedbythetestsofnormalityaccording
to Shapiro-Wilk. It was found that the data do not have
a normal distribution at P<0.05; therefore, we used
only nonparametric methods. For statistical estimation, we
used Kruskal-Willis test, followed by multiple comparison
with Mann-Whitney test with Bonferroni correction, and
Wilcoxon test. The level of statistical signiﬁcance of the
Table 1: Characteristics of the analyzed group.
MM MGUS
N 156 78
Age median (years) 65 (range 32–86) 62 (range 31–86)
M/F ratio 1,08:1 0,56:1
MIg type
IgG 98 (63%) 60 (77%)
IgA 43 (27%) 14 (18%)
Bence-Jones 14 (9%) 3 (4%)
IgD 1 (1%) —
Biclonal — 1
κ/λ ratio 2,55 1,7
MM stage
ISS 1 98 (63%) —
ISS 2 39 (25%) —
ISS 3 19 (12%) —
DS I 15 (10%) —
DS II 71 (46%) —
DS III 70 (44%) —
Substage A 149 (96%) —
Substage B 7 (4%) —
Kruskal-Willis test was P<0.05; in individual Mann-
Whitney tests, the signiﬁcance level after Bonferroni correc-
tion was P<0.0083.
3. Results
The overall diﬀerence within the assessment of all three
parameters (HGF, OPN, SYN) in MGUS and individual
phases of MM course (i.e., at the time of diagnosis, in
relapse/progression and in remission of the disease) was sta-
tistically signiﬁcant (P<0.0001). There were no signiﬁcant
diﬀerences between serum levels of HGF, SYN, and OPN
within gender, Durie: Salmon (DS) staging (although there
was a trend of higher levels of HGF and OPN in more
advanced stages) or the International Stratiﬁcation System
(ISS).
Assessment of serum levels of HGF revealed statistically
signiﬁcant diﬀerences between medians (M) in patients
with MM at diagnosis and in remission (M 2001,0 versus
1049,0pg/mL, P<0,0001), and in patients with MM
in relapse/progression and in remission (M 1370,0 versus
1049,0pg/mL, P<0,0001), whereas the diﬀerence in HGF
levels between patients at the time of diagnosis and in
relapse/progression was not statistically signiﬁcant (P =
0,051), Figure 1. Similar results showed the analysis of
OPN and SYN. Within the assessment of serum levels of
SYN, statistically signiﬁcant diﬀerences of the medians were
between the disease at the time of diagnosis and in remission
(M 103,25 versus 31,06ng/mL, P<0,0001), and in
relapse/progression versus remission of MM (M 58,0 versus
31,06ng/mL, P<0,0001), whereas the diﬀerence between
newly diagnosed and progressing MM was not signiﬁcant,The Scientiﬁc World Journal 3
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Figure 1: Comparison of serum levels of hepatocyte growth factor
(HGF) in diﬀerent phases of multiple myeloma and in monoclonal
gammopathy of undetermined signiﬁcance. Vertical axis: serum
levels of hepatocyte growth factor (HGF, pg/mL). Horizontal axis:
(A) multiple myeloma at the time of diagnosis, (B) multiple
myeloma (MM) in relapse/progression, (C) remission phase mul-
tiple myeloma, (D) monoclonal gammopathy of undetermined
signiﬁcance (MGUS). The diﬀerences between active phase MM
(A versus B) and remission phase myeloma and MGUS (C and
D) were not statistically diﬀerent. Signiﬁcant diﬀerences were
found between MM at the time of diagnosis and remission phase
myeloma (A versus C; M 2001,0 versus 1049,0pg/mL, P<0,0001),
MM at the time of diagnosis and MGUS (A versus D; 2001,0
versus 1228,0pg/mL, P<0,0001), MM in relapse/progression and
remission phase MM (B versus C; M 1370,0 versus 1049,0pg/mL,
P<0,0001), and MM in relapse/progression and MGUS (B versus
D; 1370,0 versus 1228,0pg/mL, P = 0,0002).
showing just a trend (P = 0,041), Figure 2. Serum levels
of OPN were signiﬁcantly diﬀerent only between MM at
the time of diagnosis and in remission (M 123,1 versus
66,55ng/mL, P = 0,0003). The levels of OPN between MM
in relapse/progression and in remission (M 74,975 versus
66,55ng/mL), and between MM at the time of diagnosis
and in relapse/progression (M 123,1 versus 74,975) were not
statistically signiﬁcant (P = 0,101), Figure 3.
All three parameters, that is, HGF, SYN, and OPN had
signiﬁcantly higher levels when comparing active MM (at
the time of diagnosis and in relapse/progression) to MGUS.
HGF had the following serum levels at the time of diagnosis,
in relapse/progression and in MGUS: M 2001,0 and 1370,0
versus 1228,0 (P<0,0001 and P = 0,0002). The levels of
SYN were as follows: M 103,25 and 58,0 versus 28,0 (P<
0,0001 and P<0,0001). The levels of OPN were M 123,1
and 74,975 versus 52,485 (P<0,0001 and P = 0,0001).
The levels of HGF, SYN, and OPN were not diﬀerent when
comparing remission phase MM to MGUS (P = 0,343).
The assessment of the predictive value of the three
parameters revealed the following results: there was no
statistically signiﬁcant relationship between initial levels of
any of the three molecules (HGF, SYN, and OPN) and
the achievement of MM response. The same results were
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Figure 2: Comparison of serum levels of syndecan-1 (SYN)
in diﬀerent phases of multiple myeloma and in monoclonal
gammopathy of undetermined signiﬁcance. Vertical axis: serum
levels of syndecan-1 (SYN, ng/mL). Horizontal axis: (A) multiple
myeloma at the time of diagnosis, (B) multiple myeloma (MM)
in relapse/progression, (C) remission phase multiple myeloma, (D)
monoclonal gammopathy of undetermined signiﬁcance (MGUS).
The diﬀerences between active phase MM (A versus B), and
remission phase myeloma and MGUS (C and D) were not
statistically diﬀerent. Signiﬁcant diﬀerences were found between
MM at the time of diagnosis and remission phase myeloma (A
versus C; M 103,25 versus 31,06ng/mL, P<0,0001), MM at
the time of diagnosis and MGUS (A versus D; M 103,25 versus
28,0ng/mL,P<0,0001),MMinrelapse/progressionandremission
phase MM (B versus C; M 58,0 versus 31,06ng/mL, P<0,0001),
and MM in relapse/progression and MGUS (B versus D; M 58,0
versus 28,0ng/mL, P<0,0001).
derived when comparing all patients with active disease and
within the assessment of the subgroup of patients at the time
of diagnosis and in relapse/progression of MM (Table 2).
There was only a borderline signiﬁcance for the prediction
of therapeutic response based on the initial levels of SYN at
the time of diagnosis.
In the subanalysis of patients responding after ASCT, the
results were similar regardless of the depth of therapeutic
response. Patients achieving >PR had signiﬁcantly lower
levels of the three parameters (HGF, SYN, and OPN) in
comparison with initial measurement (P = 0,0003, P =
0,005, and P = 0,033 resp.).
4. Discussion
Angiogenesis plays a key role in MM pathogenesis [6, 7].
Vaccaetal.haveﬁrstdescribedmarkedlyincreasedangiogen-
esis in MM in comparison with MGUS [8]. Since then, it has
been intensively studied and correlated to plasma cell prolif-
eration as well as to the malignant transformation [9]. Some
studies have shown that angiogenesis has a prognostic value
in MM [9, 10]. It aﬀects the pathogenesis in two ways: the
newly formed blood vessels supply the tumor with oxygen
and nutrients, and angiogenesis modulates the interaction4 The Scientiﬁc World Journal
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Figure 3: Comparison of serum levels of osteopontin (OPN)
in diﬀerent phases of multiple myeloma and in monoclonal
gammopathy of undetermined signiﬁcance. Vertical axis: serum
levels of osteopontin (OPN, OSTEOP, ng/mL). Horizontal axis:
(A) multiple myeloma at the time of diagnosis, (B) multiple
myeloma (MM) in relapse/progression, (C) remission phase mul-
tiple myeloma, (D) monoclonal gammopathy of undetermined
signiﬁcance (MGUS). The diﬀerences between active phase MM
(A versus B) and remission phase myeloma and MGUS (C and
D) were not statistically diﬀerent. The diﬀerence between MM in
relapse/progression and remission phase MM was not signiﬁcant,
either. Signiﬁcant diﬀerences were found between MM at the time
of diagnosis and remission phase myeloma (A versus C; M 123,1
versus 66,55ng/mL, P = 0,0003), MM at the time of diagnosis and
MGUS (A versus D; M 123,1 versus 52,485ng/mL, P<0,0001),
and MM in relapse/progression and MGUS (B versus D; M 74,975
versus 52,485ng/mL, P = 0,0001).
Table 2: Diﬀe r e n c e so fp r e t r e a t m e n ts e r u ml e v e l so fh e p a t o c y t e
growth factor, syndecan-1, and osteopontin in multiple myeloma
treatment responders and nonresponders.
Treatment
responders
(median)
Treatment
nonresponders
(median)
P-value
HGF diagnosis 2139,0 1627,0 0,114
HGF relapse 1365,0 1549,0 0,958
SYN diagnosis 151,0 46,2 0,041
SYN relapse 46,9 78,6 0,589
OPN diagnosis 131,5 110,8 0,448
OPN relapse 60,3 76,4 0,133
HGF: hepatocyte growth factor (pg/mL), SYN: syndecan-1 (ng/mL), OPN:
osteopontin (ng/mL). Treatment responders: patients achieving ≥ partial
remissionaftertreatment;nonresponders:patientswhodidnotreachpartial
remission and/or were progressing after treatment.
Statistical estimation was done using Mann-Whitney test at P<0,05. Only
the pretreatment serum levels of soluble syndecan-1 showed borderline
signiﬁcant diﬀerences in comparison of treatment responders and nonre-
sponders.
of myeloma plasmocytes with stromal cells by paracrine
stimulation of tumor cell migration and proliferation [9].
Among all potential angiogenic cytokines, hepatocyte
growth factor has been acknowledged as the pivotal factor
involved in multiple myeloma angiogenesis. HGF is mainly
producedbybonemarrow.Itpromotescellgrowth,invasion,
motility, and neovascularisation via its receptor, c-MET,
which is highly expressed in epithelial cells and also in MM
plasmocytes [11, 12]. In the context of multiple myeloma,
HGF was found to have an impact on bone disease, too. It
promotes the formation of osteoclasts from hematopoetic
precursor cells, attracts them to sites of bone resorption,
and also inhibits bone morphogenic protein (BMP)—
induced osteoblastogenesis [13–15]. On the other hand, its
concentrations vary during bone marrow harvesting which
might account for conﬂicting results in some MM studies
[16]. The concentrations of HGF in peripheral blood are
less likely aﬀected by the technique of harvesting and should
therefore better correspond to the activity of the disease [2].
Moreover, positive correlation between serum levels of HGF
and bone marrow microvessel density was reported [3].
Patients with multiple myeloma have signiﬁcantly higher
levels of HGF than healthy controls [17]. The behavior of
hepatocyte growth factor levels after treatment has been
a l r e a d yd o c u m e n t e db ys e v e r a lr e p o r t s[ 17, 18]. In accord-
ance with our ﬁndings, the authors describe a decrease in
HGF levels with treatment response, and an increase during
the disease relapse. Our paper in addition compares serum
levels of HGF in the most prominent phases of multiple
myeloma, that is, at the time of diagnosis, in remission
and in relapse/progression of the disease in compari-
son with MGUS. Possible role of HGF as an auxiliary
diagnostic and prognostic tool documented by signiﬁcant
diﬀerences between active disease and premalignant MGUS
or remission phase myeloma is, however, attenuated by
certain overlapping of marginal values in all the groups.
Nevertheless, the decrease of HGF after treatment expects a
relationship of HGF to the activity of the disease, suggesting
its application in the assessment of therapeutic response
and/or the evaluation of the disease progression.
Our ﬁndings oppose to the studies of Pour, and
Svachova et al. who suggested the role of HGF as a predictive
factor for MM treatment response using ASCT, conventional
therapy,andthalidomideorbortezomib-basedregimens[19,
20]. Having a larger cohort, our study did not unambigu-
ously ﬁnd signiﬁcant diﬀerences in therapeutic outcomes
based on HGF levels in any treatment arm. According to
our ﬁndings, the levels of HGF more likely correspond to
the activity of the disease and are higher in more advanced
stages of MM, similarly as in the study of Alexandrakis et al.
[2]. Together with the limitations of a small group statistics,
correspondence of HGF levels to the extent of MM might be
the reason for the poor outcome in patients with high levels
of HGF treated in the mentioned studies.
Osteopontin is a glycoprotein involved in angiogenesis,
adhesion, cell proliferation, and apoptosis [21]. It is pro-
duced by many cell types such as lymphocytes, osteoclasts,
or endothelial cells. Several studies described elevated serum
levels of OPN in multiple myeloma, in comparison with
both normal subjects as well as MGUS individuals [4, 22].
OPN is produced by osteoclasts and especially directly
by plasma cells, and it is thought to stimulate tumor
proliferation together with proangiogenic eﬀect on bloodThe Scientiﬁc World Journal 5
vessels, endothelial cell survival, and migration [21]. High
expression of OPN inversely correlates with myeloma bone
disease [23].
A very recent paper by Sﬁridaki et al. describes the role
of OPN in MM bone destruction and angiogenesis [24].
In accordance with our ﬁndings, the serum levels of OPN
correlated with the activity of the disease and decreased
after treatment. Our ﬁndings contribute by adding the
relationship of OPN serum levels behavior and therapeutic
outcome. Nevertheless, similarly as in the case of HGF,
pretreatment levels of OPN had no impact on the ﬁnal
eﬀect of the therapy. Interestingly, OPN did not correlate
with HGF, suggesting an eﬀect on diﬀerent pathways in the
regulation of both, angiogenesis, and myeloma proliferation
regulation.
Syndecan-1/CD138 is a transmembrane proteoglycan
expressed by most myeloma plasma cells [25]. Its role in
MM includes the regulation of adhesion, migration, and
promotionofproliferationbymediatingtheeﬀectsofgrowth
factors in plasma cells. Recent papers have concedeed also its
role in endothelial invasion and angiogenesis [26]. Similarly
as some other membrane proteins, it can be cleaved from
the cell surface and released into the extracellular and later
intravascular compartment. High serum levels of soluble
syndecan-1 have been acknowledged as an indicator of
poor prognosis [27]. Our previous studies conﬁrmed the
role of SYN in the transformation of MGUS into MM
and its superiority among several other bioactive molecules
in prognostication of MM overall survival in the era of
conventional therapy [1, 28]. The presented study showed
the limitations for the utilization of SYN as a robust prog-
nosticator. Despite its signiﬁcant diﬀerences between active
M Ma n dM G U S ,a n de v e nb e t w e e na c t i v ea n dr e m i s s i o n
phase MM, the levels of SYN themselves were not capable
of the distinction between the diﬀerent phases of the disease.
Marginal values in all the groups were overlapping, disabling
a clear identiﬁcation of individual phases. Similarly as in the
caseofHGForOPN,serumlevelsofSYNcorrelatedwiththe
activity of MM rather than with its future outcome.
Our results support the role of hepatocyte growth factor,
syndecan, and osteopontin in the transformation of MGUS
into MM and in the activity of MM. It is not, however,
evident, whether these diﬀerences contribute primarily to
the evolution of symptomatic disease or whether they are
the result of multiple myeloma eﬀect on the bone marrow
microenvironment. Nevertheless, the absolute levels of these
parameters could become convenient auxiliary tools for the
diﬀerentiation of MM and MGUS, and especially in the
setting of initial (asymptomatic, smoldering) MM. Similarly,
signiﬁcant decrease of HGF, SYN, and OPN in the course of
the disease corresponds to the disease activity and might be
helpfulintheassessmentoftherapeuticresponse aswellasin
the choice of individualized approach.
On the other hand, we have not conﬁrmed the predictive
role of any of these parameters for the achievement of
therapeutic response in any of the regimens used (con-
ventional chemotherapy, high-dosed chemotherapy with
support of ASCT, and thalidomide-based regimens). We
therefore conclude that the serum levels of HGF, SYN, and
OPN are likely to reﬂect the activity of MM rather than its
aggressiveness or resistance to therapy.
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